Patents Issued in March 11, 2014
  • Patent number: 8669239
    Abstract: The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and prevent tumor formation and progression and to inhibit tumor cell aggressiveness. The invention further provides methods of inhibiting tumor cell growth and/or treating aggressive tumors in a mammal comprising administering to the mammal, having at least one tumor cell present in its body, an effective amount of an inhibitor of Nodal activity.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: March 11, 2014
    Assignee: Ann & Robert H. Lurie Children's Hospital of Chicago
    Inventors: Mary Jessica Hendrix, Lynne-Marie Postovit, Richard Edward Barnet Seftor, Elisabeth Ann Seftor
  • Patent number: 8669240
    Abstract: Disclosed are compositions for isolating populations of nucleic acids from biological, forensic, and environmental samples. Also disclosed are methods for using these compositions as one-step formulations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing or assay. The disclosed compositions safely facilitate rapid sample collection, and provide extended storage and transport of the samples at ambient or elevated temperature without contamination of the sample or degradation of the nucleic acids contained therein. This process particularly facilitates the collection of specimens from remote locations, and under conditions previously considered hostile for presenting the integrity of nucleic acids released from lysed biological samples without the need of refrigeration or freezing prior to molecular analysis.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: March 11, 2014
    Assignee: Longhorn Vaccines & Diagnostics, LLC
    Inventors: Gerald W. Fischer, Luke T. Daum
  • Patent number: 8669241
    Abstract: The ophthalmic composition of the invention comprises (A) lecithin and (B) at least one refrigerant selected from the group consisting of camphor, borneol, eucalyptus oil, and bergamot oil. In the ophthalmic composition, the odor of lecithin is efficiently masked by the refrigerant. The odor of lecithin after aging is also masked by the refrigerant. Since the refrigerant is volatile, the concentration thereof in a composition tends to gradually decrease. It is surprising that the odor of lecithin after aging can nevertheless be masked.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: March 11, 2014
    Assignee: Rohto Pharmaceutical Co., Ltd.
    Inventors: Yasuko Matsumura, Mariyo Kato
  • Patent number: 8669242
    Abstract: The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of testosterone and a 5-HT1A agonist.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: March 11, 2014
    Assignee: Emotional Brain B.V.
    Inventors: Jan Johan Adriaan Tuiten, Johannes Martinus Maria Bloemers, Robertus Petrus Johannes De Lange
  • Patent number: 8669243
    Abstract: The present invention relates to steroid-derived cyclopamine analogs and methods for using the same for inhibiting sonic hedgehog signaling and preventing or treating cancer. A method for synthesizing the analogs of the present invention from a steroid is also provided.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: March 11, 2014
    Assignees: The Wistar Institute, The Trustees of the University of Pennsylvania
    Inventors: Nadia Dahmane, Jeffrey D. Winkler
  • Patent number: 8669244
    Abstract: Disclosed is a cucurbitane-triterpenoid compound for activating estrogen receptor activity, and a pharmaceutical composition, use and preparation method thereof. The cucurbitane-triterpenoid compound is presented as formula (I): wherein a single bond or a double bond is formed between C5 and C10, and a single bond or a double bond is fromed between C8 and C9; when a single bond is formed between C5 and C10, the R1 is oxygen; while a single bond is formed between C8 and C9, R2 is carbonyl group (—C?O), methyl hydroxyl group (—CH(OH)), methyl ketone or methyl dimethoxy group (—CH(OCH3)2); and wherein while R1 is oxygen (—O—) and R2 is carbonyl group (—C?O) or methyl hydroxyl group (—CH(OH)), a single bond is formed between R1 (—O—) and C19 of R2 such that R1 and R2 are formed tetrahydro-2H-pyran-2-one or hemiacetal ring.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: March 11, 2014
    Assignee: National Taiwan University
    Inventors: Ching-Jang Huang, Yueh-Hsiung Kuo, Chin Hsu
  • Patent number: 8669245
    Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: March 11, 2014
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Patent number: 8669246
    Abstract: A substituted amide compound is useful as an active ingredient of a pharmaceutical composition, in particular a pharmaceutical composition for treating diseases caused by lysophosphatidic acid (LPA). The compound is of a formula: In this formula, A is an optionally substituted aryl, etc.; B is an optionally substituted 5-membered aromatic hetero ring group; X is a single bond or —(CRX1RX2)n—; n is 1, 2, 3, or 4; RX1 and RX2 are hydrogen, etc.; Y1 to Y5 are each CRY or N; each RY is hydrogen, etc.; R1 and R2 are hydrogen, etc.; m is 1, 2, or 3; R3 is hydrogen, etc.; and R4 is an optionally substituted lower alkyl, etc.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: March 11, 2014
    Assignee: Astellas Pharma Inc.
    Inventors: Eiji Kawaminami, Tatsuhisa Takahashi, Takatoshi Kanayama, Yuta Fukuda, Hiroyuki Kaizawa, Yutaka Kondoh, Ryushi Seo, Kazuyuki Kuramoto, Kazuhiko Take, Kazuyuki Sakamoto
  • Patent number: 8669247
    Abstract: Provided herein are 2,5-disubstituted arylsulfonamides that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: March 11, 2014
    Assignee: Axikin Pharmaceuticals, Inc.
    Inventors: Tai Wei Ly, Marie Chantal Siu-Ying Tran, Erik Dean Raaum
  • Patent number: 8669248
    Abstract: In general, the present invention relates to small molecule inhibitors of the heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of neurodegenerative diseases.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: March 11, 2014
    Inventors: John Montana, Janusz Kulagowski, Hazel Hunt, Yukari Perrella
  • Patent number: 8669249
    Abstract: Compounds of the following formula are provided for use in inhibiting Poly (ADP-ribose) Polymerase (PARP): wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: March 11, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Anthony R. Gangloff, Andrew John Jennings, Phong H. Vu
  • Patent number: 8669250
    Abstract: The present invention concerns compounds of general formula (1) (I) wherein R1 is: —a hydrogen atom, or a halogen, —a straight or branched C1-C6 alkyl group or a C1-C3 fluoroalkyl group, —a straight or branched C1-C6 alcoxy group, a carbamyl group, N-substituted or not by one or two, straight or branched C1-C3 alkyl groups, or —a cyano group (CN) R2 is: —a hydrogen atom or a straight or branched C1-C6 alkyl group, HaI1, Hal2 and Hal3 are: —a halogen their addition salts and the hydrates of addition salts with pharmaceutically acceptable mineral acids or organic acids, and their enantiomer forms.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: March 11, 2014
    Assignee: Pierre Fabre Medicament
    Inventors: Bernard Vacher, Francis Colpaert, Jean-Louis Maurel
  • Patent number: 8669251
    Abstract: 8-Fluorophthalazin-1(2h)-one compounds of Formula II where one or two of X1, X2, and X3 are N, are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula II for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: March 11, 2014
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, Daniel Fred Ortwine, BinQing Wei, Wendy B. Young
  • Patent number: 8669252
    Abstract: Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: March 11, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Dong-Ming Shen, John S. Debenham, Thomas H. Graham, Matthew J. Clements, Yong Zhang
  • Patent number: 8669253
    Abstract: Inhibition of geranylgeranylation of Rho GTPases and heterotrimeric G-proteins in the aqueous outflow pathway increases aqueous humor outflow, possibly through the tissue relaxation, and through altered cell adhesive interactions and actin cytoskeletal organization in cells of the outflow pathway. In addition, such inhibition is useful for treating age-related macular degeneration. The GGTase-I enzyme is a molecular target for lowering increased ocular pressure in glaucoma patients.
    Type: Grant
    Filed: March 12, 2007
    Date of Patent: March 11, 2014
    Assignee: Duke University
    Inventors: Vasantha P. Rao, Patrick J. Casey, Peifeng Deng, Yuri K. Peterson
  • Patent number: 8669254
    Abstract: The present invention relates to compounds of the formula wherein A1 to A3 and R1 to R9 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: March 11, 2014
    Assignee: Hoffman-La Roche Inc.
    Inventors: Paul Hebeisen, Stephan Roever
  • Patent number: 8669255
    Abstract: The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein Z1, Z2, Z3, Z4, R1, R2, and R3 are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use as calcium channel inhibitors.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: March 11, 2014
    Assignee: AbbVie Inc.
    Inventors: Tao Li, Sachin V. Patel, Richard J. Perner, John T. Randolph, Michael R. Schrimpf, Kevin R. Woller, Zhiren Xia, Qingwei Zhang
  • Patent number: 8669256
    Abstract: The invention relates to compounds according to general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of cancer.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: March 11, 2014
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Brigitte Johanna Bernita Folmer, de Adrianus Petrus Antonius Man, Elisabeth Sophia Gernette, Rita Corte Real Goncalves Azevedo, Hemen Ibrahim
  • Patent number: 8669257
    Abstract: The present invention provides compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein each of W, Q, R1, R2, R3, R4, R5, m, and n is as defined herein, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: March 11, 2014
    Assignee: The Johns Hopkins University
    Inventors: Jun O. Liu, Yunzhao Ren, Fan Pan, Curtis R. Chong, Reinhold Penner, Jonathan R. Behr
  • Patent number: 8669258
    Abstract: Embodiments of the invention are directed to the treatment of gastroparesis by administering sepiapterin.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: March 11, 2014
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Pankaj J. Pasricha, Pandu R. R. Gangula
  • Patent number: 8669259
    Abstract: The present invention relates to heterocyclic amide derivatives of Formula (I): Formula (I) wherein the variables are as defined in the specification. The present invention further relates to compositions comprising said heterocyclic amide derivatives of formula (I) and methods for using said heterocyclic amide derivatives of formula (I) for treating or preventing a disease or disorder related to the activity of a protein kinase, in particular, a proliferative disease, an anti-proliferative disorder, inflammation, arthritis, a neurological or neurodegenerative disease, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease or a fungal infection.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: March 11, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Panduranga P. Adulla Reddy, M. Arshad Siddiqui, Tzu Tshin Wong
  • Patent number: 8669260
    Abstract: The application discloses ketoconazole derivatives that are antagonists of the human pregnane X receptor (PXR), methods of preparing the derivatives, uses of the derivatives with drug therapy, and methods of inhibiting tumor cell proliferation and multidrug resistance using inhibitors of PXR.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: March 11, 2014
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Sridhar Mani, Bhaskar C. Das
  • Patent number: 8669261
    Abstract: Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R?, R?, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: March 11, 2014
    Assignee: Congenia SLR
    Inventors: Daniele Fancelli, Mario Varasi, Simon Plyte, Marco Ballarini, Anna Cappa, Giacomo Carenzi, Saverio Minucci, Gilles Pain, Manuela Villa
  • Patent number: 8669262
    Abstract: The present invention relates to the compound of the formula: or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: March 11, 2014
    Assignee: Parion Sciences, Inc.
    Inventor: Michael R. Johnson
  • Patent number: 8669263
    Abstract: This disclosure concerns antimicrobial compositions and methods for immunoenhancement, for example methods of increasing production of a type I interferon (IFN) in response to pathogen infection, by administration of a TAM receptor inhibitor. In certain embodiments, the disclosure concerns methods of using a TAM receptor inhibitor to treat a viral or bacterial infection in a subject.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: March 11, 2014
    Assignee: Salk Institute for Biological Studies
    Inventors: Greg E. Lemke, John A. T. Young, Carla V. Rothlin, Suchita Bhattacharyya
  • Patent number: 8669264
    Abstract: The teachings provided herein generally relate to compositions comprising rutaecarpine derivatives that activates CYP1A2 through enzyme induction. The uses for such a derivative can include removing caffeine from a subject, improving sleep, treating insomnia, treating caffeine toxicity, treating caffeine addiction and withdrawal symptoms, and the like. Caffeine is just one example of a substrate that can be removed using the derivatives taught herein, and other examples, including theophylline, are provided herein.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: March 11, 2014
    Assignee: Linnet Biopharmaceuticals, Inc.
    Inventors: Liang Xue, William K. Chan, Stan W. Linnet, Timothy N. Linnet
  • Patent number: 8669265
    Abstract: The present invention provides a novel and stable hydrated form of erlotinib free base, and a process for its preparation thereof. The present invention also provides a process for preparation of erlotinib hydrochloride crystalline polymorph a substantially free of polymorph B. The present invention further relates to erlotinib hydrochloride crystalline particles having mean particle size (D50) ranging from about 4 ?m to 15 ?m and 90 volume-% of the particles (D90) ranging from about 14 ?m to 30 ?m, to the methods for the manufacture of said crystalline particles, and to pharmaceutical compositions comprising said crystalline particles.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: March 11, 2014
    Assignee: Hetero Drugs Limited
    Inventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Rapolu Raji Reddy, Dasari Muralidhara Reddy, Thungathurthy Srinivas Rao
  • Patent number: 8669266
    Abstract: The present invention relates to compounds of the formula I, in which R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: October 5, 2009
    Date of Patent: March 11, 2014
    Assignee: Sanofi
    Inventors: Marc Nazare, Gernot Zech, Melitta Just, Tilo Weiss, Gerhard Hessler, Joerg Czech
  • Patent number: 8669267
    Abstract: There is provided a pharmaceutical agent, food, or beverage for treating or preventing a disease or condition that can be ameliorated by inhibiting serotonin reuptake, comprising a clinically-effective amount of (1S,3S)-1-methyl-1,2,3,4-tetrahydro-?-carboline-3-carboxylic acid.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: March 11, 2014
    Assignee: Suntory Holdings Limited
    Inventors: Yoshinori Beppu, Nobuo Tsuruoka, Hajime Komura
  • Patent number: 8669268
    Abstract: The present application describes deuterium-enriched prasugrel, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: August 22, 2008
    Date of Patent: March 11, 2014
    Assignee: DeuteRx, LLC
    Inventor: Anthony W Czarnik
  • Patent number: 8669269
    Abstract: The present invention relates to substituted imidazo[1,2-a]pyridines of formula I where R is —CH2COOH or —COOH, which inhibits exogenously or endogenously stimulated gastric acid secretion and can be used in the prevention and treatment of gastric acid related diseases and gastrointestinal inflammatory diseases.
    Type: Grant
    Filed: October 27, 2009
    Date of Patent: March 11, 2014
    Inventor: Mikael Dahlstrom
  • Patent number: 8669270
    Abstract: The present invention relates to SNS-595 and methods of treating cancer using the same.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: March 11, 2014
    Assignees: Dainippon Sumitomo Pharma Co., Ltd., Sunesis Pharmaceuticals, Inc.
    Inventors: Masaru Higaki, Satoshi Nakao
  • Patent number: 8669271
    Abstract: The present invention relates to compounds of formula I, wherein the groups R1, LP, LQ, X1, X2, X3, Ar and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: March 11, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Frank Himmelsbach, Matthias Eckhardt, Niklas Heine, Elke Langkopf, Bernd Nosse
  • Patent number: 8669272
    Abstract: The present invention is directed to 2,5-disubstituted piperidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: March 11, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, John D. Schreier, David B. Whitman
  • Patent number: 8669273
    Abstract: A combination of a 4-anilino-3-cyanoquinoline compound (e.g. HKI-272, SKI-606, EKB-569) and a capecitabine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: March 11, 2014
    Assignee: Wyeth LLC
    Inventors: Charles Michael Zacharchuk, Susan Elizabeth Quinn, Kenneth Kuan-Yuen Wang, Florence Marie Helene Binlich
  • Patent number: 8669274
    Abstract: The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: March 11, 2014
    Assignee: Viamet Pharmaceuticals, Inc.
    Inventors: William J. Hoekstra, Robert J. Schotzinger, Stephen W. Rafferty
  • Patent number: 8669275
    Abstract: The present application describes deuterium-enriched donepezil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: March 11, 2014
    Assignee: DeuteRx, LLC
    Inventor: Anthony W. Czarnik
  • Patent number: 8669276
    Abstract: The present application describes deuterium-enriched lenalidomide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: September 9, 2012
    Date of Patent: March 11, 2014
    Assignee: Deuteria Pharmaceuticals, Inc.
    Inventor: Anthony W. Czarnik
  • Patent number: 8669277
    Abstract: Disclosed are solid forms of 1-[4-[4-[5-(2,6-difluorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (Compound 1). Methods for the preparation of solid forms of Compound 1 and for the conversion of one solid form of Compound 1 into another are disclosed. Disclosed are fungicidal compositions comprising a fungicidally effective amount of a solid form of Compound 1 and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid carriers. Compositions comprising a mixture of a solid form of Compound 1 and at least one other fungicide or insecticide are also disclosed. Also disclosed are methods for controlling plant diseases caused by fungal plant pathogens comprising applying to a plant or portion thereof, or to a plant seed, a fungicidally effective amount of a solid form of Compound 1.
    Type: Grant
    Filed: April 19, 2010
    Date of Patent: March 11, 2014
    Assignee: E I du Pont de Nemours and Company
    Inventors: Matthew Richard Oberholzer, Robert James Pasteris, Rafael Shapiro
  • Patent number: 8669278
    Abstract: N-Substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines are effective at controlling insects.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: March 11, 2014
    Assignee: Dow AgroSciences, LLC.
    Inventors: Michael R. Loso, Benjamin M. Nugent, Jim X. Huang, Richard B. Rogers, Yuanming Zhu, James M. Renga, Vidyadhar B. Hegde, Joseph J. DeMark
  • Patent number: 8669279
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: March 11, 2014
    Assignee: Cephalon, Inc.
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Patent number: 8669280
    Abstract: The present invention relates to novel compounds and compositions having antiviral activity. The invention also relates to methods for the therapeutic or prophylactic treatment of viral infections in mammals.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: March 11, 2014
    Assignee: Biotron Limited
    Inventors: Gary Dinneen Ewart, Wayne Morris Best
  • Patent number: 8669281
    Abstract: The present invention provides compounds of formula (I), wherein: R1 is unsubstituted C1-C6 alkyl; La is substituted or unsubstituted C1-C6 alkyl linker, substituted or unsubstituted C3-C10 carbocycle, substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, or substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S; and R2 and R3 are each, independently, H, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C6-C10 aryl; or alternatively, R2 and R3, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S or a substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: March 11, 2014
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Tarek A. Zeidan, Scott Duncan, Christopher P. Hencken, Thomas Andrew Wynn, Carlos N. Sanrame
  • Patent number: 8669282
    Abstract: The invention encompasses compositions and methods for treating or preventing disorders in companion animals, wherein the compositions and methods include feeding the companion animal a composition including lipoic acid or a salt thereof.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: March 11, 2014
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Steven C. Zicker, Nolan Zebulon Frantz
  • Patent number: 8669283
    Abstract: The present invention relates to specific beta-lactone compounds and compositions thereof for the treatment of infections, such as, e.g., infections with bacteria or infections with protozoa, in particular infections with Gram-positive and/or Gram-negative bacteria and of infectious diseases caused by or related to Gram-positive and/or Gram-negative bacteria, and to the modulation of virulence of Gram-positive and/or Gram-negative bacteria or of protozoa by specific beta-lactone compounds. The invention further relates to the use of the compounds or compositions for preventing or eliminating biofilms.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: March 11, 2014
    Assignee: Ludwig-Maximilians-Universitat Munchen
    Inventors: Stephan A. Sieber, Thomas Böttcher
  • Patent number: 8669284
    Abstract: Disclosed is a method for stabilizing a pharmaceutically active bi-cyclic compound of formula (I): comprising the step of: admixing the same with a polyol and/or a fatty acid ester other than glyceride and a composition obtained by the method. In addition a soft gelatin capsule formulation of the compound of formula (I) obtained by incorporating the compound in a soft gelatin capsule shell comprising gelatin and a polyol plasticizer.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: March 11, 2014
    Assignees: Sucampo AG, R-Tech Ueno, Ltd.
    Inventors: Ryu Hirata, Yasuhiro Harada, Ryuji Ueno
  • Patent number: 8669285
    Abstract: The present invention provides novel cycloalkylmethylamine analogs, and methods of preparing cycloalkylmethylamine analogs. The present invention also provides methods of using cycloalkylmethylamine analogs and compositions of cycloalkylmethylamine analogs. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: March 11, 2014
    Assignee: Reviva Pharmaceuticals, Inc.
    Inventors: Laxminarayan Bhat, Seema Rani Bhat
  • Patent number: 8669286
    Abstract: This invention is directed to a feed composition and method of affecting the carcass composition by increasing the lean mass, reducing the fat mass, and/or reducing the percent fat mass comprising SARM compounds.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: March 11, 2014
    Assignee: University of Tennessee Research Foundation
    Inventors: James T. Dalton, Duane D. Miller, Jeffrey D. Kearbey
  • Patent number: 8669287
    Abstract: An emulsifying preparation for an oil-soluble component, which is sensorily superior when applied to an aqueous phase, can maintain stability for a long time, and imposes less restriction for formulation or production is provided. The emulsifying preparation of the present invention contains (A) an oil phase component containing an oil-soluble component, (B) an aqueous phase component containing a polyol, and (C) an emulsifier containing polyglycerol fatty acid monoester having an average degree of polymerization of not less than 10, and having an HLB value of not less than 14 and not more than 18 or showing a transmittance of 1 wt % aqueous solution at 600 nm of not less than 80%.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: March 11, 2014
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yoko Shimagami, Yasushi Ichimi
  • Patent number: 8669288
    Abstract: The present invention is directed to a novel lysine salts, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by PPAR delta. The present invention is further directed to a novel process for the preparation of said lysine salts.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: March 11, 2014
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Ahmed F. Abdel-Magid, Steven J. Mehrman, Armin Roessler